Clinical Trials Logo
  1. Home
  2. Cocaine-Related Disorders
  3. NCT00000248
  4. Details
NCT00000248 Clinical Trial

Dose Response Trial of Pergolide for Cocaine Dependence - 1

Cocaine-Related Disorders Clinical Trial

Official title:
Dose Response Trial of Pergolide for Cocaine Dependence

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00000248
Other study ID # NIDA-08355-1
Secondary ID R01DA008355R01-0
Status Completed
Phase Phase 3
First received
Last updated
Start date February 1996

Study information
Verified date May 1997
Source National Institute on Drug Abuse (NIDA)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of pergolide for treatment of cocaine dependence.

Recruitment information / eligibility
Status Completed
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 21 Years to 50 Years
Eligibility Please contact site for information.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Pergolide

Locations
Country Name City State
United States Medical University of South Carolina Charleston South Carolina

Sponsors (2)
Lead Sponsor Collaborator
Medical University of South Carolina National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Malcolm R, Moore JW, Kajdasz DK, Cochrane CE. Pergolide mesylate. Adverse events occurring in the treatment of cocaine dependence. Am J Addict. 1997 Spring;6(2):117-23. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary Side effects
Primary Drug use
Primary Retention
Primary Cocaine withdrawal
Primary Compliance
Primary Effectiveness of medication for global improvements
See also
  Status Clinical Trial Phase
Completed NCT01526538 - Improving Learning-based Treatment of Cocaine Dependence With Medication Phase 2
Completed NCT00877435 - Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial N/A
Completed NCT00430690 - Acoustic Startle Reduction In Cocaine Dependence
Completed NCT00217997 - Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals N/A
Active, not recruiting NCT00094315 - Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1 Phase 1
Terminated NCT00142883 - The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3 N/A
Completed NCT00218348 - Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo Phase 2
Completed NCT00158132 - Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2 Phase 2
Completed NCT00142844 - Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 Phase 2
Completed NCT00015054 - Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3 Phase 2
Completed NCT00000294 - Effects of Carvedilol on Cocaine Use in Humans - 11 Phase 2
Completed NCT00000308 - Dextroamphetamine-Cocaine Behavioral Intervention - 5 Phase 2
Completed NCT00000314 - M-CPP and Fenfluramine in Cocaine Addicts - 3 Phase 2
Completed NCT00000278 - Disulfiram for Cocaine-Alcohol Abuse - 3 Phase 2
Completed NCT00000280 - Glutaminergic Agents for Cocaine Abuse - 5 Phase 1
Terminated NCT00000276 - Dopamine Reuptake Inhibitors of Cocaine Abuse - 1 Phase 1
Completed NCT00000306 - Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3 Phase 2
Completed NCT00000188 - Selegiline in Treatment of Cocaine Dependence - 2 Phase 2
Completed NCT00000277 - Mazindol for Cocaine Abuse - 2 Phase 2
Completed NCT00000282 - Pemoline for Cocaine Abuse - 7 Phase 2